Jeremy Snider

Publication Activity (10 Years)

Years Active: 2015-2022
Publications (10 Years): 4

Top Topics

Metastatic Colorectal Cancer

Mitochondrial Dna

Epidermal Growth Factor Receptor

Squamous Cell Carcinoma

Top Venues

JCO precision oncology

Future oncology (London, England)

JMIR mental health

JMIR mHealth and uHealth

This page only lists publications with an associated author ORCID identifier.

Publications

Carsten Schröder, Craig Gower-Page, Irmarie Reyes-Rivera, Arisha Patel, Richard Price, Shiraj Sen, Jessica Davies, Emily H Castellanos, Jeremy Snider, Xiaobo Bai, Virginia A Fisher, Shivani K Mhatre
Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. JCO clinical cancer informatics 6 (2022)
Liangliang Zhang, Omar Hamdani, Ole V Gjoerup, Cheryl Cho-Phan, Jeremy Snider, Emily H Castellanos, Halla Nimeiri, Garrett M Frampton, Jeffrey M Venstrom, Geoffrey R Oxnard, Samuel J Klempner, Alexa B Schrock
ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. JCO precision oncology 6 (2022)
Stacey M Stein, Jeremy Snider, Siraj M Ali, Rebecca A Miksad, Brian M Alexander, Emily H Castellanos, Alexa B Schrock, Russell W Madison, Akshay Swaminathan, Jeffrey M Venstrom, Margaret McCusker
Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future oncology (London, England) 17 (31) (2021)
William Douglas Evans, Elizabeth Louise Andrade, Sandra Goldmeer, Michelle Smith, Jeremy Snider, Gunilla Girardo
The Living the Example Social Media Substance Use Prevention Program: A Pilot Evaluation. JMIR mental health 4 (2) (2017)
William Douglas Evans, Peter E Nielsen, Daniel R Szekely, Jasmine W Bihm, Elizabeth A Murray, Jeremy Snider, Lorien C Abroms
Dose-response effects of the text4baby mobile health program: randomized controlled trial. JMIR mHealth and uHealth 3 (1) (2015)